Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel

Abstract Chimeric antigen receptor T‐cell therapy with axicabtagene ciloleucel (axi‐cel) has considerably improved survival in adults with relapsed/refractory large B‐cell lymphoma. This study reports patient‐reported outcomes (PROs) such as quality of life (QOL) and toxicity in the first 90 days af...

Full description

Bibliographic Details
Main Authors: Aasha I. Hoogland, Reena V. Jayani, Aaron Collier, Nathaly Irizarry‐Arroyo, Yvelise Rodriguez, Michael D. Jain, Margaret Booth‐Jones, Kelly A. Hyland, Brian W. James, Anna Barata, Christina A. Bachmeier, Julio C. Chavez, Farhad Khimani, Gabriel S. Krivenko, Aleksandr Lazaryan, Hien D. Liu, Taiga Nishihori, Javier Pinilla‐Ibarz, Bijal D. Shah, Muneer Abidi, Frederick L. Locke, Heather S. L. Jim
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
behavioral science
hematological cancer
lymphoma
quality of life
Online Access:https://doi.org/10.1002/cam4.3664

Internet

https://doi.org/10.1002/cam4.3664

Similar Items